REVB (Revelation Biosciences) Current Accrued Expense: $0.47 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

REVB Revelation Biosciences Inc REVB
28 GF Score
Price $1.14
! 1 Warning Sign
View Full Analysis

What is Revelation Biosciences Current Accrued Expense?

Revelation Biosciences REVB +1.79% 28 Current Accrued Expense is $0.47 Mil as of Mar. 2026. GuruFocus rates REVB with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Revelation Biosciences's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.47 Mil.

Revelation Biosciences's quarterly Current Accrued Expense increased from Sep. 2025 ($0.82 Mil) to Dec. 2025 ($1.40 Mil) but then declined from Dec. 2025 ($1.40 Mil) to Mar. 2026 ($0.47 Mil).

Revelation Biosciences's annual Current Accrued Expense declined from Dec. 2023 ($1.15 Mil) to Dec. 2024 ($1.13 Mil) but then increased from Dec. 2024 ($1.13 Mil) to Dec. 2025 ($1.40 Mil).

Revelation Biosciences Current Accrued Expense Related Terms

Revelation Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Revelation Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revelation Biosciences Current Accrued Expense Chart

Revelation Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 1.53 0.99 1.15 1.13 1.40

Revelation Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.74 0.82 1.40 0.47
REVB
28GF Score
Revelation Biosciences Inc REVB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revelation Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.47 Mil mean?
Revelation Biosciences (REVB) has a Current Accrued Expense of $0.47 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Revelation Biosciences and its competitors.
Is Revelation Biosciences' Current Accrued Expense too high?
Revelation Biosciences' current Current Accrued Expense is $0.47 Mil. Overall, Revelation Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Revelation Biosciences' Current Accrued Expense compare to ELAB and ENSC?
Revelation Biosciences' Current Accrued Expense of $0.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Revelation Biosciences and its competitors. Revelation Biosciences's current Current Accrued Expense is $0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revelation Biosciences stock overvalued right now?
Revelation Biosciences (REVB) has a current Current Accrued Expense of $0.47 Mil. The current Current Accrued Expense is $0.47 Mil. Revelation Biosciences' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Revelation Biosciences (REVB), the current Current Accrued Expense is $0.47 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revelation Biosciences Business Description

Address 4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
28GF Score

Get the complete analysis for REVB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price